公开(公告)号：US09186410B2

公开(公告)日：2015-11-17

申请号：US13581463

申请日：2011-03-01

申请人： Helen Burt ,  Donald Brooks ,  Jayachandran Kizhakkedathu ,  Richard Liggins ,  Dechi Guan ,  Lu Ye ,  Clement Mugabe ,  Alan So ,  Martin E. Gleave ,  John K. Jackson ,  Rajesh Kumar Kainthan

发明人： Helen Burt ,  Donald Brooks ,  Jayachandran Kizhakkedathu ,  Richard Liggins ,  Dechi Guan ,  Lu Ye ,  Clement Mugabe ,  Alan So ,  Martin E. Gleave ,  John K. Jackson ,  Rajesh Kumar Kainthan

IPC分类号： A61K33/24 ,  C07C217/00 ,  C07D207/46 ,  A61K47/10 ,  A61K9/51 ,  A61K47/34 ,  C08G65/34 ,  C08G65/48 ,  C08G83/00 ,  C08G65/333 ,  A61K9/00

CPC分类号： A61K47/10 ,  A61K9/0034 ,  A61K9/006 ,  A61K9/5146 ,  A61K31/337 ,  A61K31/407 ,  A61K33/24 ,  A61K47/34 ,  A61K47/60 ,  C08G65/33306 ,  C08G65/33337 ,  C08G65/34 ,  C08G65/48 ,  C08G83/005 ,  C08G83/006 ,  C08G2650/54

摘要： Herein are provided derivatized hyperbranched polyglycerols (“dHPGs”). The dHPG comprises a core comprising a hyperbranched polyglycerol derivatized with C1C20 alkyl chains and a shell comprising at least one hydrophilic substituent bound to hydroxyl groups of the core, wherein the hyperbranched polyglycerol comprises from about 1 to about 200 moles of the at least one hydrophilic substituent. The dHPGs are for use as agents for the delivery of a drug or other biologically active moiety to the urinary tract, the digestive tract, the airways, the vaginal cavity and cervix and the peritoneal cavity to treat indications such as cancer, which may be useful in the treatment of or the manufacture of a medicament, in the preparation, of a pharmaceutical composition for the treatment of cancer, as a pre-treatment or co-treatment to improve drug uptake in a tissue. Furthermore, there are provided methods of making dHPGs.

摘要翻译： 本文提供衍生的超支化聚甘油（“dHPG”）。 dHPG包含核心，其包含用C1C20烷基链衍生的超支化聚甘油和包含至少一个与核心羟基结合的亲水取代基的壳，其中超支化聚甘油包含约1至约200摩尔的至少一个亲水取代基 。 dHPG用作将药物或其他生物活性部分递送至尿路，消化道，气道，阴道腔和子宫颈以及腹膜腔以治疗诸如癌症的适应症的药剂，其可能是有用的 在制备中用于治疗癌症的药物组合物的治疗或制造中，作为用于改善组织中药物摄取的预处理或共处理。 此外，还提供了制造dHPG的方法。

公开(公告)号：US20130122112A1

公开(公告)日：2013-05-16

申请号：US13581463

申请日：2011-03-01

申请人： Helen M. Burt ,  Donald Brooks ,  Jayachandran Kizhakkedathu ,  Richard Liggins ,  Dechi Guan ,  Lu Ye ,  Clement Mugabe ,  Alan So ,  Martin E. Gleave ,  John K. Jackson ,  Rajesh Kumar Kainthan

发明人： Helen M. Burt ,  Donald Brooks ,  Jayachandran Kizhakkedathu ,  Richard Liggins ,  Dechi Guan ,  Lu Ye ,  Clement Mugabe ,  Alan So ,  Martin E. Gleave ,  John K. Jackson ,  Rajesh Kumar Kainthan

IPC分类号： A61K47/10 ,  C08G65/333

CPC分类号： A61K47/10 ,  A61K9/0034 ,  A61K9/006 ,  A61K9/5146 ,  A61K31/337 ,  A61K31/407 ,  A61K33/24 ,  A61K47/34 ,  A61K47/60 ,  C08G65/33306 ,  C08G65/33337 ,  C08G65/34 ,  C08G65/48 ,  C08G83/005 ,  C08G83/006 ,  C08G2650/54

摘要： Herein are provided derivatized hyperbranched polyglycerols (“dHPGs”). The dHPG comprises a core comprising a hyperbranched polyglycerol derivatized with C1C20 alkyl chains and a shell comprising at least one hydrophilic substituent bound to hydroxyl groups of the core, wherein the hyperbranched polyglycerol comprises from about 1 to about 200 moles of the at least one hydrophilic substituent. The dHPGs are for use as agents for the delivery of a drug or other biologically active moiety to the urinary tract, the digestive tract, the airways, the vaginal cavity and cervix and the peritoneal cavity to treat indications such as cancer, which may be useful in the treatment of or the manufacture of a medicament, in the preparation, of a pharmaceutical composition for the treatment of cancer, as a pre-treatment or co-treatment to improve drug uptake in a tissue. Furthermore, there are provided methods of making dHPGs.

摘要翻译： 本文提供衍生的超支化聚甘油（“dHPG”）。 dHPG包含核心，其包含用C1C20烷基链衍生的超支化聚甘油和包含至少一个与核心羟基结合的亲水取代基的壳，其中超支化聚甘油包含约1至约200摩尔的至少一个亲水取代基 。 dHPG用作将药物或其他生物活性部分递送至尿路，消化道，气道，阴道腔和子宫颈以及腹膜腔以治疗诸如癌症的适应症的药剂，其可能是有用的 在制备中用于治疗癌症的药物组合物的治疗或制造中，作为用于改善组织中药物摄取的预处理或共处理。 此外，还提供了制备dHPG的方法。

公开(公告)号：US20050175661A1

公开(公告)日：2005-08-11

申请号：US10999205

申请日：2004-11-29

申请人： William Hunter ,  David Gravett ,  Philip Toleikis ,  Arpita Maiti ,  Pierre Signore ,  Richard Liggins ,  Dechi Guan

发明人： William Hunter ,  David Gravett ,  Philip Toleikis ,  Arpita Maiti ,  Pierre Signore ,  Richard Liggins ,  Dechi Guan

IPC分类号： A61B17/00 ,  A61B17/11 ,  A61B17/12 ,  A61F2/00 ,  A61F2/86 ,  A61F13/00 ,  A61K38/48 ,  A61L27/00 ,  A61L27/54 ,  A61L31/00 ,  A61L31/16 ,  A61M29/00 ,  A61M31/00

CPC分类号： A61B17/12172 ,  A61B17/00491 ,  A61B17/11 ,  A61B17/12022 ,  A61B17/12045 ,  A61B17/12136 ,  A61B17/1215 ,  A61B17/12177 ,  A61B17/12186 ,  A61B17/1219 ,  A61B2017/00004 ,  A61F2/86 ,  A61F2250/0067 ,  A61L31/16 ,  A61L2300/412

摘要： Intravascular devices (e.g., stents, stent grafts, covered stents, aneurysm coils, embolic agents and drug delivery catheters and balloons) are used in combination with fibrosing agents in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or to promote fibrosis betweent the devices and the host tissues. Compositions and methods are described for use in the treatment of aneurysms and unstable arterial (vulnerable) plaque.

公开(公告)号：US20050149175A1

公开(公告)日：2005-07-07

申请号：US11007719

申请日：2004-12-07

申请人： William Hunter ,  David Gravett ,  Philip Toleikis ,  Arpita Maiti ,  Pierre Signore ,  Richard Liggins ,  Dechi Guan

发明人： William Hunter ,  David Gravett ,  Philip Toleikis ,  Arpita Maiti ,  Pierre Signore ,  Richard Liggins ,  Dechi Guan

IPC分类号： A61B17/00 ,  A61B17/11 ,  A61B17/12 ,  A61F2/00 ,  A61F2/86 ,  A61F13/00 ,  A61K38/48 ,  A61L27/00 ,  A61L27/54 ,  A61L31/00 ,  A61L31/16 ,  A61M29/00 ,  A61M31/00 ,  A61F2/06

CPC分类号： A61B17/12172 ,  A61B17/00491 ,  A61B17/11 ,  A61B17/12022 ,  A61B17/12045 ,  A61B17/12136 ,  A61B17/1215 ,  A61B17/12177 ,  A61B17/12186 ,  A61B17/1219 ,  A61B2017/00004 ,  A61F2/86 ,  A61F2250/0067 ,  A61L31/16 ,  A61L2300/412

摘要： Intravascular devices (e.g., stents, stent grafts, covered stents, aneurysm coils, embolic agents and drug delivery catheters and balloons) are used in combination with fibrosing agents in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or to promote fibrosis betweent the devices and the host tissues. Compositions and methods are described for use in the treatment of aneurysms and unstable arterial (vulnerable) plaque.

公开(公告)号：US20050149173A1

公开(公告)日：2005-07-07

申请号：US10986450

申请日：2004-11-10

申请人： William Hunter ,  David Gravett ,  Philip Toleikis ,  Arpita Maiti ,  Pierre Signore ,  Richard Liggins ,  Dechi Guan

发明人： William Hunter ,  David Gravett ,  Philip Toleikis ,  Arpita Maiti ,  Pierre Signore ,  Richard Liggins ,  Dechi Guan

IPC分类号： A61B17/00 ,  A61B17/11 ,  A61B17/12 ,  A61F2/00 ,  A61F2/86 ,  A61F13/00 ,  A61K38/48 ,  A61L27/00 ,  A61L27/54 ,  A61L31/00 ,  A61L31/16 ,  A61M29/00 ,  A61M31/00 ,  A61F2/06

CPC分类号： A61B17/12172 ,  A61B17/00491 ,  A61B17/11 ,  A61B17/12022 ,  A61B17/12045 ,  A61B17/12136 ,  A61B17/1215 ,  A61B17/12177 ,  A61B17/12186 ,  A61B17/1219 ,  A61B2017/00004 ,  A61F2/86 ,  A61F2250/0067 ,  A61L31/16 ,  A61L2300/412

摘要： Intravascular devices (e.g., stents, stent grafts, covered stents, aneurysm coils, embolic agents and drug delivery catheters and balloons) are used in combination with fibrosing agents in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or to promote fibrosis betweent the devices and the host tissues. Compositions and methods are described for use in the treatment of aneurysms and unstable arterial (vulnerable) plaque.

公开(公告)号：US20080146652A1

公开(公告)日：2008-06-19

申请号：US11834498

申请日：2007-08-06

申请人： Richard Liggins ,  Larry Murphy ,  Dechi Guan

发明人： Richard Liggins ,  Larry Murphy ,  Dechi Guan

IPC分类号： A61K31/337 ,  A61K47/32 ,  A61P35/00

CPC分类号： A61K31/337 ,  A61K9/0019 ,  A61K9/107 ,  A61K9/19

摘要： Anhydrous formulations are formed of a diblock copolymer (X-Y) having a hydrophilic block X comprising residues of monomer x, and a hydrophobic block Y comprising residues of monomer y; an additive selected from a polymer and an organic solvent, where the solvent is water-miscible and biocompatible, and the polymer is hydrophobic or hydrophilic and comprises residues of monomers x and/or y, the polymer optionally having a molecular weight that is less than the molecular weight of the diblock copolymer; and a drug. Upon admixture with water, the anhydrous formulations form drug delivery vehicles, preferably in micellar form. The inclusion of polymer and/or organic solvent provides for the formation of micelles at an enhanced rate, and/or provides the formation of micelles having an enhanced ability to incorporate drug(s), and/or provides the formation of micelles having advantageous physical characteristics, e.g., advantageous viscosity and/or melting point.

公开(公告)号：US20050186243A1

公开(公告)日：2005-08-25

申请号：US11000097

申请日：2004-11-29

申请人： William Hunter ,  David Gravett ,  Philip Toleikis ,  Arpita Maiti ,  Pierre Signore ,  Richard Liggins ,  Dechi Guan

发明人： William Hunter ,  David Gravett ,  Philip Toleikis ,  Arpita Maiti ,  Pierre Signore ,  Richard Liggins ,  Dechi Guan

IPC分类号： A61B17/00 ,  A61B17/11 ,  A61B17/12 ,  A61F2/00 ,  A61F2/86 ,  A61F13/00 ,  A61K38/48 ,  A61L27/00 ,  A61L27/54 ,  A61L31/00 ,  A61L31/16 ,  A61M29/00 ,  A61M31/00

CPC分类号： A61B17/12172 ,  A61B17/00491 ,  A61B17/11 ,  A61B17/12022 ,  A61B17/12045 ,  A61B17/12136 ,  A61B17/1215 ,  A61B17/12177 ,  A61B17/12186 ,  A61B17/1219 ,  A61B2017/00004 ,  A61F2/86 ,  A61F2250/0067 ,  A61L31/16 ,  A61L2300/412

摘要： Intravascular devices (e.g., stents, stent grafts, covered stents, aneurysm coils, embolic agents and drug delivery catheters and balloons) are used in combination with fibrosing agents in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or to promote fibrosis betweent the devices and the host tissues. Compositions and methods are described for use in the treatment of aneurysms and unstable arterial (vulnerable) plaque.

公开(公告)号：US20050181004A1

公开(公告)日：2005-08-18

申请号：US11006289

申请日：2004-12-07

申请人： William Hunter ,  David Gravett ,  Philip Toleikis ,  Arpita Maiti ,  Pierre Signore ,  Richard Liggins ,  Dechi Guan

发明人： William Hunter ,  David Gravett ,  Philip Toleikis ,  Arpita Maiti ,  Pierre Signore ,  Richard Liggins ,  Dechi Guan

IPC分类号： A61B17/00 ,  A61B17/11 ,  A61B17/12 ,  A61F2/00 ,  A61F2/86 ,  A61F13/00 ,  A61K38/48 ,  A61L27/00 ,  A61L27/54 ,  A61L31/00 ,  A61L31/16 ,  A61M29/00 ,  A61M31/00

CPC分类号： A61B17/12172 ,  A61B17/00491 ,  A61B17/11 ,  A61B17/12022 ,  A61B17/12045 ,  A61B17/12136 ,  A61B17/1215 ,  A61B17/12177 ,  A61B17/12186 ,  A61B17/1219 ,  A61B2017/00004 ,  A61F2/86 ,  A61F2250/0067 ,  A61L31/16 ,  A61L2300/412

摘要： Intravascular devices (e.g., stents, stent grafts, covered stents, aneurysm coils, embolic agents and drug delivery catheters and balloons) are used in combination with fibrosing agents in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or to promote fibrosis betweent the devices and the host tissues. Compositions and methods are described for use in the treatment of aneurysms and unstable arterial (vulnerable) plaque.

公开(公告)号：US20050165467A1

公开(公告)日：2005-07-28

申请号：US11006048

申请日：2004-12-07

申请人： William Hunter ,  David Gravett ,  Philip Toleikis ,  Arpita Maiti ,  Pierre Signore ,  Richard Liggins ,  Dechi Guan

发明人： William Hunter ,  David Gravett ,  Philip Toleikis ,  Arpita Maiti ,  Pierre Signore ,  Richard Liggins ,  Dechi Guan

IPC分类号： A61B17/00 ,  A61B17/11 ,  A61B17/12 ,  A61F2/00 ,  A61F2/86 ,  A61F13/00 ,  A61K38/48 ,  A61L27/00 ,  A61L27/54 ,  A61L31/00 ,  A61L31/16 ,  A61M29/00 ,  A61M31/00 ,  A61F2/06

CPC分类号： A61B17/12172 ,  A61B17/00491 ,  A61B17/11 ,  A61B17/12022 ,  A61B17/12045 ,  A61B17/12136 ,  A61B17/1215 ,  A61B17/12177 ,  A61B17/12186 ,  A61B17/1219 ,  A61B2017/00004 ,  A61F2/86 ,  A61F2250/0067 ,  A61L31/16 ,  A61L2300/412

摘要： Intravascular devices (e.g., stents, stent grafts, covered stents, aneurysm coils, embolic agents and drug delivery catheters and balloons) are used in combination with fibrosing agents in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or to promote fibrosis betweent the devices and the host tissues. Compositions and methods are described for use in the treatment of aneurysms and unstable arterial (vulnerable) plaque.

公开(公告)号：US20050186242A1

公开(公告)日：2005-08-25

申请号：US10999204

申请日：2004-11-29

申请人： William Hunter ,  David Gravett ,  Philip Toleikis ,  Arpita Maiti ,  Pierre Signore ,  Richard Liggins ,  Dechi Guan

发明人： William Hunter ,  David Gravett ,  Philip Toleikis ,  Arpita Maiti ,  Pierre Signore ,  Richard Liggins ,  Dechi Guan

IPC分类号： A61B17/00 ,  A61B17/11 ,  A61B17/12 ,  A61F2/00 ,  A61F2/86 ,  A61F13/00 ,  A61K38/48 ,  A61L27/00 ,  A61L27/54 ,  A61L31/00 ,  A61L31/16 ,  A61M29/00 ,  A61M31/00

CPC分类号： A61B17/12172 ,  A61B17/00491 ,  A61B17/11 ,  A61B17/12022 ,  A61B17/12045 ,  A61B17/12136 ,  A61B17/1215 ,  A61B17/12177 ,  A61B17/12186 ,  A61B17/1219 ,  A61B2017/00004 ,  A61F2/86 ,  A61F2250/0067 ,  A61L31/16 ,  A61L2300/412

摘要： Intravascular devices (e.g., stents, stent grafts, covered stents, aneurysm coils, embolic agents and drug delivery catheters and balloons) are used in combination with fibrosing agents in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or to promote fibrosis betweent the devices and the host tissues. Compositions and methods are described for use in the treatment of aneurysms and unstable arterial (vulnerable) plaque.